Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04623502 · ClinicalTrials.gov registry record · NA

An Investigation of Kidney and Urothelial Tumor Metabolism in Patients Undergoing Surgical Resection and/or Biopsy

A NA study of Renal Cell Carcinoma and Urothelial Carcinoma, sponsored by University of Texas Southwestern Medical Center.

Recruiting
Registry status
NA
Development phase
600
Enrollment target
1
Study location

NCT04623502: Recruiting NA study of Renal Cell Carcinoma and Urothelial Carcinoma, sponsored by University of Texas Southwestern Medical Center.

NCT04623502 is a NA study of Renal Cell Carcinoma and Urothelial Carcinoma that is actively recruiting participants, run by University of Texas Southwestern Medical Center. The registered enrollment target is 600 participants, above the 238-participant average among 121 other Renal Cell Carcinoma trials with a reported enrollment target (152% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04623502, a NA study of Renal Cell Carcinoma and Urothelial Carcinoma, is actively recruiting participants, sponsored by University of Texas Southwestern Medical Center.

RECRUITING
Registry status
NA
Development phase
600 participants
Enrollment target
1
Study location

Study Summary

The purpose of this study is to understand the metabolism of cancers involving the kidney, including renal cell carcinomas and urothelial cell carcinomas, and how kidney cancers use different types of fuel to support tumor growth. This study uses specially labeled nutrient tracers of compounds normally found circulating in the blood. The nutrients (glucose, fructose, glutamine, acetate, and lactate) are also found in common foods. A nutrient tracer will be given to the participants through an intravenous (IV) catheter during surgery or biopsy, and blood will be collected every 30 minutes during the infusion to monitor safety parameters and the nutrient tracers. The investigators will collect a tissue sample after the completion of surgery. Participants not having an infusion will have their tissue collected after surgery or biopsy. Participation in this study will not change patient care. All patients will receive standard of care treatment as determined by their doctors.

Primary Outcome

Tissue and blood samples will be analyzed for 13C isotopologue distributions (percent) in central carbon metabolites using mass spectrometry. This allows the Investigators to understand how different subtypes of kidney and urothelial cancers alter utilization of the 13C tracers.

Interventions

  • OTHER 13C-Glucose
  • OTHER 13C-Acetate
  • OTHER 13C-Lactate
  • OTHER 13C-Glutamine
  • OTHER 13C-Fructose

Study Locations (1)

Texas

  • University of Texas Southwestern Medical Center - Dallas

Trial Details

FieldValue
Enrollment Target 600 participants
Start Date 2019-09-30
Est. Completion 2027-09-30
Phase NA

What NCT04623502 shows while recruiting

NCT04623502 is an interventional study that assigns participants to a tested intervention. The registered 600 participants enrollment target is mid-sized for trials with a published cap, above the 238-participant average among 121 other Renal Cell Carcinoma trials with a reported enrollment target (152% higher).

The record links to 10 conditions, with Renal Cell Carcinoma appearing as the primary indexed condition, and to 5 interventions - of which 13C-Glucose is the first listed.

NCT04623502 reports a single indexed study location in Texas.

Frequently Asked Questions

What is clinical trial NCT04623502 about?

NCT04623502 is a clinical study titled "An Investigation of Kidney and Urothelial Tumor Metabolism in Patients Undergoing Surgical Resection and/or Biopsy". The purpose of this study is to understand the metabolism of cancers involving the kidney, including renal cell carcinomas and urothelial cell carcinomas, and how kidney cancers use different types of fuel to support tumor growth. This study uses specially labeled nutrient tracers of compounds norma...

What is the current status of trial NCT04623502?

This trial is currently recruiting. It is a NA study. The enrollment target is 600 participants. The study started on 2019-09-30. Estimated completion is 2027-09-30.

What conditions does trial NCT04623502 study?

This clinical trial studies the following conditions: Renal Cell Carcinoma, Urothelial Carcinoma, Kidney Cancer, Metastatic Urothelial Carcinoma, Chromophobe Renal Cell Carcinoma.

What interventions are being tested in trial NCT04623502?

The interventions under investigation include: 13C-Glucose (OTHER), 13C-Acetate (OTHER), 13C-Lactate (OTHER), 13C-Glutamine (OTHER), 13C-Fructose (OTHER).

Who is sponsoring clinical trial NCT04623502?

This trial is sponsored by University of Texas Southwestern Medical Center, which has 837 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04623502 being conducted?

This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Renal Cell Carcinoma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT04623502's enrollment target sits among peer trials

600 13th of 121 higher than 109 of 121 other Renal Cell Carcinoma trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Renal Cell Carcinoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00004317 · 600 participants · Phase 4

    Pyrimethamine, Sulfadiazine, and Leucovorin in Treating Patients With Congenital Toxoplasmosis

  • NCT00209235 · 600 participants · NA

    Albright Hereditary Osteodystrophy: Natural History, Growth, and Cognitive/Behavioral Assessments

  • NCT01473784 · 600 participants · NA

    Transoral Robotic Surgery in Treating Patients With Benign or Malignant Tumors of the Head and Neck

  • NCT01866371 · 600 participants

    High Resolution Retinal Imaging

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT04623502, the US trial registry maintained by the National Library of Medicine. NCT04623502 (mid enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.